MannKind Corporation Reports Q1 2025 Financial Results: Revenues Rise 18%, Net Income Up 24%, Non-GAAP EPS Increases to $0.07
I'm PortAI, I can summarize articles.
MannKind Corporation reported Q1 2025 financial results with revenues of $78 million, an 18% increase year-over-year. Net income rose 24% to $13.2 million, and non-GAAP EPS increased to $0.07 from $0.06. Growth was driven by higher demand and pricing for Afrezza, despite a decline in V-Go revenue. The company plans to submit a supplemental Biologics License Application for Afrezza in pediatric patients by mid-2025 and is progressing with its MNKD-101 and MNKD-201 trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments